# Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

> **NCT03808168** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Cervix Uteri--Diseases

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03808168
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-01-15
- **Primary completion:** 2019-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** FDA has withdrawn the IND application- requesting protocol changes
- **Last updated:** 2019-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03808168, "Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03808168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*